ClinicalTrials.gg
CompletedNCT02307513Updated Jul 22, 2021Results posted

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

A Phase 3 interventional study of Apremilast and Placebo in Behçet's Syndrome, sponsored by Amgen. Completed at 63 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-22.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).

Read the detailed description

Behçet's disease, is a rare disorder that causes inflammation in blood vessels throughout the body. The signs and symptoms of Behçet's disease may include mouth sores, eye inflammation, skin rashes and lesions, and genital sores that vary from person to person and may come and go on their own. The exact cause of Behçet's is unknown, but it may be an autoimmune disorder, which means the body's immune system mistakenly attacks some of its own healthy cells.

This study will evaluate if apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment of oral ulcers in subjects with active Behçet's disease. Other manifestations of the disease will also be assessed, such as, pain and tenderness in joints, eye inflammation, genital ulcers, and skin disease. This study also will test how well the body tolerates apremilast. In addition, the second purpose of the study is to assess the safety of apremilast in patients with Behçet's disease.

This study is a randomized, placebo-controlled, parallel design. The placebo-controlled period will be 12 weeks long and participants will receive apremilast or placebo. After the 12-week placebo-controlled period, all participants will receive apremilast for 52 weeks in the active treatment period. All participants will have their final study visit 4 weeks after stopping apremilast treatment.

Participants in Germany will have the opportunity to enter an optional open-label extension phase after the 52-week active treatment phase (week 64 visit), and continue until apremilast is commercially available for Behçet's disease or until apremilast is found not to be acceptable for Behçet's disease, according to either the sponsor or health authority.

02

Conditions studied

  • Behçet's Syndrome

Browse trials for

Keywords

  • APREMILAST (CC-10004)
  • CC-10004
  • Efficacy
  • Safety
  • Phase 3
  • Behçet's Disease
03

In context

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

This study's enrollment of 207 is above the median of 50 across 70 interventional studies indexed under Behcet Syndrome.

Browse Behcet Syndrome studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Understand and voluntarily sign an document prior to any study related assessments/procedures being conducted.
  2. Male and female subjects ≥ 18 years of age at the time of signing the informed consent document.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Diagnosed with Behcet's disease meeting th4 International Study Group (ISG) criteria,
  5. Oral ulcers that occurred at least 3 times in the previous 12-month period, including oral ulcers at the screening visit.
  6. Subjects must have at least 2 oral ulcers at Visit 1 (Screening Visit), and:

    1. At least 2 oral ulcers at Visit 2 (day of randomization), when Visit 2 occurs at least 14 days after Visit 1. OR
    2. At least 3 oral ulcers at Visit 2 (day of randomization), when Visit 2 occurs at any time between 1 day and 42 days after Visit 1.
  7. Have prior treatment with at least 1 non-biologic Behçet's disease therapy, such as, but not limited to, topical , or systemic treatment.
  8. Candidate for systemic therapy, for the treatment of oral ulcers.

    a. A candidate for systemic therapy is a subject judged by the study Investigator as someone whose mucocutaneous ulcers are considered inappropriate for topical therapy based on the severity of disease and extent of the affected area, or whose oral ulcers cannot be adequately controlled by topical therapy.

  9. Laboratory Measures: Must meet the following laboratory measures:

    • > 9 g/dL
    • White blood cell (WBC) count ≥ 3000 /L(≥ 3.0 X 10\^9/L) and ≤ 14,000/L (≤ 14 X 10\^9/L )
    • count ≥ 100,000 /L (≥ 100 X 10\^9/L)
    • Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
    • Total ≤ 2.0 mg/dL
    • (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) ≥ 1.5 X . Subjects who fail screening due to ≥ 1.5 X ULN AST/SGOT and/or ALT/SGPT will be allowed to repeat AST/SGOT and/or ALT/SGPT tests within the screening phase. Repeat test results should be ≤ ULN (within reference range) to be eligible.

Laboratory tests will be allowed to be repeated 1 time if, in the Investigator's clinical judgment, there is a reasonable possibility of the repeat tests not meeting the exclusion values, and with concurrence from the Medical Monitor.

Requirements:

All Females of Child Bearing Potential (FCBP) must use one of the approved contraceptive options as described below while taking apremilast and for at least 28 days after administration of the last dose of the apremilast.

At the time of study entry, and at any time during the study when a FCBP's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.

All FCBP must have a negative pregnancy test at Visits 1 and 2. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex or non-latex condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while on IP and for at least 28 days after the last dose of IP.

Exclusion Criteria: The presence of any of the following will exclude a subject from the study enrollment.

Disease Specific Exclusions:

  1. Behçet's disease-related active major organ involvement - pulmonary (eg, pulmonary artery aneurysm), vascular (eg, thrombophlebitis), gastrointestinal (eg, ulcers along the gastrointestinal tract), and central nervous systems (eg, meningoencephalitis) manifestations, and ocular lesions (eg, uveitis) requiring therapy; however:

    1. Previous major organ involvement is allowed if it occurred at least 1 year prior to Visit 1 (Screening Visit) and is not active at time of enrollment.
    2. Subjects with mild BD-related ocular lesions not requiring systemic immunosuppressive therapy are allowed.
    3. Subjects with BD-related arthritis and BD-skin manifestations are also allowed.
  2. Previous exposure to biologic therapies for the treatment of BD oral ulcers ( Previous biologic therapy exposure is allowed for other indications, including other manifestations of BD)
  3. Prior use of apremilast.
  4. Use of any medication within 4 weeks prior to Visit 2 or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer).
  5. Current use of strong cytochrome P450 enzyme inducers (eg, rifampin, phenobarbital, carbamazepine, phenytoin)
  6. Having received concomitant immune modulating therapy (except oral or topical corticosteroids) within:

    • Seven days prior to Visit 2 (Baseline Visit; day of randomization) for colchicines
    • Ten days prior to Visit 2 (Baseline Visit; day of randomization) for azathioprine and mycophenolate mofetil
    • Four weeks (28 days) prior to Visit 2 (Baseline Visit; day of randomization) for cyclosporine, methotrexate, cyclophosphamide, thalidomide, and dapsone.

    Note: Oral and topical corticosteroids must have been tapered as appropriate and discontinued prior to the day of Visit 2 (day of randomization).

    • At least 5 terminal half-lives for all biologics, including, but not limited to, those listed below; within:
    • Four weeks prior to Visit 2 (Baseline Visit; day of randomization) for etanercept
    • Eight weeks prior to Visit 2 (Baseline Visit; day of randomization) for infliximab
    • Ten weeks prior to Visit 2 (Baseline Visit; day of randomization) for adalimumab, golimumab, certolizumab, abatacept, and tocilizumab
    • Six months prior to Visit 2 (Baseline Visit; day of randomization) for secukinumab
  7. Having received intra-articular or parenteral corticosteroids within 6 weeks (42 days) prior to Visit 2 (Baseline Visit; day of randomization).
  8. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  9. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  10. Inability to provide voluntary consent.
  11. Pregnant women or breast feeding mothers.
  12. Systemic or opportunistic fungal infection.
  13. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, and C and herpes zoster, histoplasmosis, coccidiomycosis, but excluding onychomycosis) or any major episode of infection requiring hospitalization or treatment with IV or oral antibiotics within 4 weeks of the Screening Phase.
  14. abnormality on chest radiograph.
  15. Clinically significant abnormality on 12-lead (ECG).
  16. History of positive test for, or any clinical suspicion of, (HIV), or congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
  17. or history of malignancy, except for:

    1. treated (ie, cured) basal cell or squamous cell in situ skin carcinomas;
    2. treated (ie, cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years of Visit 1.
  18. Any condition that confounds the ability to interpret data from the study.
  19. Scheduled surgery or other interventions that would interrupt the subject's participation in the study.
  20. Prior history of suicide attempt at any time in the subject's lifetime prior to Visit 2 (Baseline Visit; day of randomization) or major psychiatric illness requiring hospitalization within 3 years prior to Visit 2 (Baseline Visit; day of randomization).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Placebo / Apremilast

    Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.

    Drug: Apremilast · Drug: Placebo

  • Experimental
    Apremilast

    Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.

    Drug: Apremilast

Interventions

  • Tablets for oral administration

    Also known as: Otezla®, CC-10004

  • DrugPlacebo

    Tablets for oral administration

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)

    The number of oral ulcers that was counted for the analysis of the primary endpoint included current and recurrent ulcers at each time point; a single oral ulcer could be recounted multiple times if it persisted or recurred at subsequent visits.

    Time frame: Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period.

Secondary outcomes

  1. Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12

    Pain of oral ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  2. Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12

    The Behçet's Syndrome Activity Score (BSAS) contains 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score ranges from 0 to 100, with a higher score indicating a higher level of disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  3. Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12

    The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, including oral and genital disease activity, as well as other manifestations of BD involving the skin, joints, GI tract, eyes, nervous system, and vascular system. The BDCAI score is the sum score of 12 items and ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  4. Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12

    The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Patient's Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  5. Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12

    The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Clinician's Overall Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  6. Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks

    Participants who were oral ulcer-free by week 6 and remained oral ulcer-free for at least 6 consecutive weeks during the 12-week placebo-controlled treatment phase.

    Time frame: Baseline to week 12

  7. Time to Oral Ulcer Resolution (Complete Response)

    Time to oral ulcer resolution (defined as oral ulcer-free) was the time between the first dose date and the date when a complete response was achieved for the first time during the placebo-controlled treatment phase. For participants who did not achieve complete response or discontinued treatment before a complete response was achieved during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment date during the placebo-controlled treatment phase or the first dose date if there were no postbaseline ulcer assessments. Median and 95% confidence interval was based on Kaplan-Meier estimates.

    Time frame: Baseline to week 12

  8. Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12

    A complete response at week 12 was defined as participants who were oral ulcer free at week 12.

    Time frame: Week 12

  9. Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12

    The Behçet's Disease Quality of Life questionnaire was developed to measure the influence of BD on a particpant's life. It consists of 30 self-completed itemized questions that measure disease-related restrictions on the participant's activities and their emotional response to these restrictions. The total score is the sum of all 30 items (each yes scores 1 and each no scores 0), with 0 representing no influence of Behçet's disease on a participant's quality of life and 30 representing the most severe influence. A negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  10. Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12

    A genital ulcer complete response at week 12 was defined as participants who were genital ulcer-free at week 12.

    Time frame: Week 12

  11. Percentage of Participants With no Oral Ulcers Following a Complete Response

    The definition includes participants who remained oral ulcer-free through week 12 after achieving a complete response (oral ulcer-free) prior to week 12.

    Time frame: Baseline to week 12

  12. Time to Recurrence of Oral Ulcers Following Loss of Complete Response

    Time to recurrence of oral ulcers following the loss of complete response (oral ulcer-free) was defined as the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. For participants who did not have oral ulcer recurrence or discontinued treatment before any oral ulcer recurrence during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment during placebo-controlled treatment phase; For participants without any oral ulcer assessment following the first complete response, time to event was censored to the first complete response date.

    Time frame: Baseline through week 12

  13. Number of Oral Ulcers Following Loss of Complete Response Through Week 12

    Number of oral ulcers reported at the time of the first loss of complete response, ie, at the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase.

    Time frame: Baseline to week 12

  14. Change From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12

    BD-related skin lesions (including acne-like lesions, folliculitis, and erythema nodosum) were evaluated according to the Static Physician's Global Assessment as follows: Score 0 = clear skin. Score 1 = mild in severity with the presence of 1 to 10 lesions (papules, pustules, cysts) or nodules at any anatomical site. Score 2 = Moderate severity; presence of 11 to 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. Score 3 = Severe; presence of \> 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. The total sore was calculated as the sum of the acne-like lesions, folliculitis, and erythema nodosum scores, and therefore ranges from 0 to 9, where a higher score indicates a higher level of activity. A negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  15. Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12

    Pain of genital ulcers was measured using a 100 mm visual analog scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.

    Time frame: Baseline to week 12

  16. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-controlled Treatment Period

    A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE (SAE) is any AE that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms; Moderate: symptoms causing moderate discomfort and local or noninvasive intervention is indicated; Severe: symptoms causing severe discomfort or pain, symptoms requiring medical/surgical intervention.

    Time frame: From first dose of study drug in the placebo-controlled phase to the first dose of apremilast in the active treatment phase (12 weeks) or up to 28 days after last dose for participants who did not receive study drug at week 12, whichever was earlier.

  17. Number of Participants With TEAEs During the Apremilast-Exposure Period

    The apremilast-exposure period started on the date of the first dose of apremilast (week 0 for participants assigned to apremilast or week 12 for participants who were originally assigned to placebo and switched to apremilast at week 12) and ended 28 days after last dose in the active treatment phase. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. An SAE is any AE that resulted in death; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. The investigator assessed the severity of each event according to the grading scale: Mild: asymptomatic or mild symptoms; Moderate: symptoms causing moderate discomfort, local or noninvasive intervention indicated; Severe: symptoms causing severe discomfort or pain, requiring medical/surgical intervention.

    Time frame: From first dose of apremilast (week 0 for those assigned to apremilast or week 12 for those assigned to placebo) up to 28 days after last dose; up to 56 weeks and 68 weeks in each arm respectively.

07

Results

Posted Sep 11, 2019

Participant flow

The study was conducted at 53 sites in Europe (France, Germany, Greece, and Italy), Asia (Japan and the Republic of Korea), the United States, and Rest of the World (Israel, Lebanon, and Turkey).

Placebo Controlled Phase (Weeks 0-12)
Participant flow — Placebo Controlled Phase (Weeks 0-12)
MilestonePlacebo/ApremilastApremilast
Started103104
Completed8396
Not completed208
Withdrew: Adverse event43
Withdrew: Lack of efficacy80
Withdrew: Non-compliance with study drug10
Withdrew: Withdrawal by subject54
Withdrew: Lost to follow-up10
Withdrew: Protocol violation11
Active Treatment Phase (Weeks 13-64)
Participant flow — Active Treatment Phase (Weeks 13-64)
MilestonePlacebo/ApremilastApremilast
Started8395
Completed6875
Not completed1520
Withdrew: Miscellaneous01
Withdrew: Adverse event49
Withdrew: Lack of efficacy22
Withdrew: Withdrawal by subject77
Withdrew: Lost to follow-up11
Withdrew: Pregnancy10
Long-term Extension
Participant flow — Long-term Extension
MilestonePlacebo/ApremilastApremilast
Started20
Completed10
Not completed10
Withdrew: Physician decision10

Outcome measures

PrimaryArea Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)

The number of oral ulcers that was counted for the analysis of the primary endpoint included current and recurrent ulcers at each time point; a single oral ulcer could be recounted multiple times if it persisted or recurred at subsequent visits.

Time frame:
Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period.
Reported as:
Least squares mean · Ulcers*days
Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)
Ulcers*daysPlaceboApremilast 30 mg BID
Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)222.14 ± 15.886129.54 ± 15.943
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = <0.0001 · Difference in ls mean: -92.60 · 95% CI -130.59 to -54.60Treatment difference = Apremilast - Placebo
SecondaryChange From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12

Pain of oral ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · mm
Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12
mmPlaceboApremilast 30 mg BID
Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12-15.9 ± 3.31-40.7 ± 3.34
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = <0.0001 · Difference in ls mean: -24.8 · 95% CI -32.8 to -16.8Based on an ANCOVA model for the change from baseline with the treatment arm, sex, region as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12

The Behçet's Syndrome Activity Score (BSAS) contains 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score ranges from 0 to 100, with a higher score indicating a higher level of disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12
Units on a scalePlaceboApremilast 30 mg BID
Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12-5.41 ± 1.776-17.35 ± 1.796
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = <0.0001 · Difference in ls mean: -11.94 · 95% CI -16.20 to -7.67Based on an ANCOVA model for the change from baseline with the treatment arm, sex, region as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12

The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, including oral and genital disease activity, as well as other manifestations of BD involving the skin, joints, GI tract, eyes, nervous system, and vascular system. The BDCAI score is the sum score of 12 items and ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12
Units on a scalePlaceboApremilast 30 mg BID
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12-0.4 ± 0.20-0.9 ± 0.20
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = 0.0335 · Difference in ls means: -0.5 · 95% CI -1.0 to -0.0Based on an ANCOVA model for the change from baseline with the treatment arm, sex, region as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12

The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Patient's Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12
Units on a scalePlaceboApremilast 30 mg BID
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12-0.7 ± 0.18-1.7 ± 0.18
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = <0.0001 · Difference in ls means: -1.0 · 95% CI -1.4 to -0.6Based on an ANCOVA model for the change from baseline with the treatment arm, sex, region as factors and the baseline value as a covariate.
SecondaryChange From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12

The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Clinician's Overall Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12
Units on a scalePlaceboApremilast 30 mg BID
Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12-0.7 ± 0.17-1.6 ± 0.17
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = <0.0001 · Difference in ls means: -0.9 · 95% CI -1.3 to -0.5Based on an ANCOVA model for the change from baseline with the treatment arm, sex, region as factors and the baseline value as a covariate.
SecondaryPercentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks

Participants who were oral ulcer-free by week 6 and remained oral ulcer-free for at least 6 consecutive weeks during the 12-week placebo-controlled treatment phase.

Time frame:
Baseline to week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks
Percentage of participantsPlaceboApremilast 30 mg BID
Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks4.929.8
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference in percentages: 25.1 · 95% CI 15.5 to 34.6Adjusted difference was the weighted average of the treatment differences across the 4 strata of combined sex and region factors with the CMH weights.
SecondaryTime to Oral Ulcer Resolution (Complete Response)

Time to oral ulcer resolution (defined as oral ulcer-free) was the time between the first dose date and the date when a complete response was achieved for the first time during the placebo-controlled treatment phase. For participants who did not achieve complete response or discontinued treatment before a complete response was achieved during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment date during the placebo-controlled treatment phase or the first dose date if there were no postbaseline ulcer assessments. Median and 95% confidence interval was based on Kaplan-Meier estimates.

Time frame:
Baseline to week 12
Reported as:
Median · Weeks
Time to Oral Ulcer Resolution (Complete Response)
WeeksPlaceboApremilast 30 mg BID
Time to Oral Ulcer Resolution (Complete Response)8.1 (4.7 to NA)2.1 (2.0 to 4.0)
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · Stratified Log-Rank Test · p = <0.0001 · Hazard ratio (hr): 2.400 · 95% CI 1.692 to 3.405The HR is based on the stratified Cox model with baseline number of oral ulcers and sex and region as the stratification factors.
SecondaryPercentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12

A complete response at week 12 was defined as participants who were oral ulcer free at week 12.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12
Percentage of participantsPlaceboApremilast 30 mg BID
Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 1222.352.9
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference in percentages: 30.6 · 95% CI 18.1 to 43.1Adjusted difference was the weighted average of the treatment differences across the 4 strata of combined sex and region factors with the CMH weights.
SecondaryChange From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12

The Behçet's Disease Quality of Life questionnaire was developed to measure the influence of BD on a particpant's life. It consists of 30 self-completed itemized questions that measure disease-related restrictions on the participant's activities and their emotional response to these restrictions. The total score is the sum of all 30 items (each yes scores 1 and each no scores 0), with 0 representing no influence of Behçet's disease on a participant's quality of life and 30 representing the most severe influence. A negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12
Units on a scalePlaceboApremilast 30 mg BID
Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12-0.5 ± 0.66-3.5 ± 0.67
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = 0.0003 · Difference in ls mean: -3.0 · 95% CI -4.5 to -1.4Based on an ANCOVA model for the change from baseline with the treatment arm, sex, region as factors and the baseline value as a covariate.
SecondaryPercentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12

A genital ulcer complete response at week 12 was defined as participants who were genital ulcer-free at week 12.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12
Percentage of participantsPlaceboApremilast 30 mg BID
Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 1241.270.6
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · Cochran-Mantel-Haenszel · p = 0.1100 · Adjusted difference in percentages: 28.4 · 95% CI -3.6 to 60.4Adjusted difference was the weighted average of the treatment differences across the 2 strata of sex with the CMH weights.
SecondaryPercentage of Participants With no Oral Ulcers Following a Complete Response

The definition includes participants who remained oral ulcer-free through week 12 after achieving a complete response (oral ulcer-free) prior to week 12.

Time frame:
Baseline to week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With no Oral Ulcers Following a Complete Response
Percentage of participantsPlaceboApremilast 30 mg BID
Percentage of Participants With no Oral Ulcers Following a Complete Response13.231.3
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · Cochran-Mantel-Haenszel · p = 0.0204 · Adjusted difference in percentages: 17.5 · 95% CI 4.2 to 30.7Adjusted difference was the weighted average of the treatment differences across the 4 strata of combined sex and region factors with the CMH weights.
SecondaryTime to Recurrence of Oral Ulcers Following Loss of Complete Response

Time to recurrence of oral ulcers following the loss of complete response (oral ulcer-free) was defined as the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. For participants who did not have oral ulcer recurrence or discontinued treatment before any oral ulcer recurrence during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment during placebo-controlled treatment phase; For participants without any oral ulcer assessment following the first complete response, time to event was censored to the first complete response date.

Time frame:
Baseline through week 12
Reported as:
Median · Weeks
Time to Recurrence of Oral Ulcers Following Loss of Complete Response
WeeksPlaceboApremilast 30 mg BID
Time to Recurrence of Oral Ulcers Following Loss of Complete Response2.3 (2.1 to 4.1)4.6 (3.1 to 6.1)
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · Stratified Log Rank Test · p = 0.0112 · Hazard ratio (hr): 0.611 · 95% CI 0.408 to 0.915The HR is based on the stratified Cox model with baseline number of oral ulcers and sex and region as the stratification factors
SecondaryNumber of Oral Ulcers Following Loss of Complete Response Through Week 12

Number of oral ulcers reported at the time of the first loss of complete response, ie, at the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · oral ulcers
Number of Oral Ulcers Following Loss of Complete Response Through Week 12
oral ulcersPlaceboApremilast 30 mg BID
Number of Oral Ulcers Following Loss of Complete Response Through Week 121.5 ± 0.211.1 ± 0.18
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = 0.0683 · Difference in ls means: -0.4 · 95% CI -0.9 to 0.0ANCOVA model with treatment group, sex and region as factors and the baseline ulcers number as a covariate.
SecondaryChange From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12

BD-related skin lesions (including acne-like lesions, folliculitis, and erythema nodosum) were evaluated according to the Static Physician's Global Assessment as follows: Score 0 = clear skin. Score 1 = mild in severity with the presence of 1 to 10 lesions (papules, pustules, cysts) or nodules at any anatomical site. Score 2 = Moderate severity; presence of 11 to 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. Score 3 = Severe; presence of \> 20 nodules or lesions (papules, pustules, cysts) at any anatomical site. The total sore was calculated as the sum of the acne-like lesions, folliculitis, and erythema nodosum scores, and therefore ranges from 0 to 9, where a higher score indicates a higher level of activity. A negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12
scores on a scalePlaceboApremilast 30 mg BID
Change From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12-0.8 ± 0.14-0.9 ± 0.14
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = 0.5944 · Difference in ls mean: -0.1 · 95% CI -0.4 to 0.3Based on an ANCOVA model for the change from baseline, with treatment arm, sex and region as factors and the baseline score as a covariate.
SecondaryChange From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12

Pain of genital ulcers was measured using a 100 mm visual analog scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement.

Time frame:
Baseline to week 12
Reported as:
Least squares mean · mm
Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12
mmPlaceboApremilast 30 mg BID
Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12-24.5 ± 10.75-30.0 ± 11.22
Statistical analysis
  • Placebo vs Apremilast 30 mg BID · ANCOVA · p = 0.6182 · Difference in ls mean: -5.5 · 95% CI -27.6 to 16.7Based on an ANCOVA model for the change from baseline, with treatment arm, sex and region as factors and the baseline score as a covariate.
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-controlled Treatment Period

A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE (SAE) is any AE that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms; Moderate: symptoms causing moderate discomfort and local or noninvasive intervention is indicated; Severe: symptoms causing severe discomfort or pain, symptoms requiring medical/surgical intervention.

Time frame:
From first dose of study drug in the placebo-controlled phase to the first dose of apremilast in the active treatment phase (12 weeks) or up to 28 days after last dose for participants who did not receive study drug at week 12, whichever was earlier.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-controlled Treatment Period
ParticipantsPlaceboApremilast 30 mg BID
Any TEAE7482
Any Drug-related TEAE3760
Any Severe TEAE66
Any Serious TEAE43
Any TEAE Leading to Drug Interruption69
Any TEAE Leading to Drug Withdrawal53
Any TEAE Leading to Death00
SecondaryNumber of Participants With TEAEs During the Apremilast-Exposure Period

The apremilast-exposure period started on the date of the first dose of apremilast (week 0 for participants assigned to apremilast or week 12 for participants who were originally assigned to placebo and switched to apremilast at week 12) and ended 28 days after last dose in the active treatment phase. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. An SAE is any AE that resulted in death; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. The investigator assessed the severity of each event according to the grading scale: Mild: asymptomatic or mild symptoms; Moderate: symptoms causing moderate discomfort, local or noninvasive intervention indicated; Severe: symptoms causing severe discomfort or pain, requiring medical/surgical intervention.

Time frame:
From first dose of apremilast (week 0 for those assigned to apremilast or week 12 for those assigned to placebo) up to 28 days after last dose; up to 56 weeks and 68 weeks in each arm respectively.
Reported as:
Count of participants · Participants
Number of Participants With TEAEs During the Apremilast-Exposure Period
ParticipantsPlacebo/ApremilastApremilast/Apremilast
Any TEAE7090
Any Drug-related TEAE2964
Any Severe TEAE417
Any Serious TEAE710
Any TEAE Leading to Drug Interruption1017
Any TEAE Leading to Drug Withdrawal312
Any TEAE Leading to Death00

Adverse events

Collected over Placebo-controlled phase: From first dose of study drug to week 12 or up to 28 days after last dose for participants who did not receive study drug at week 12. Apremilast Exposure Phase: From first dose of apremilast (week 0 or week 12 for those assigned to placebo) up to 28 days after last dose; up to 56 weeks and 68 weeks in each arm respectively. Open-label extension: From first dose of apremilast in the extension phase to 28 days after last dose, up to 784 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Phase: Placebo0/103 (0%)4/103 (3.9%)52/103 (50.5%)
Placebo-controlled Phase: Apremilast 30 mg BID0/104 (0%)3/104 (2.9%)67/104 (64.4%)
Apremilast Exposure Period: Apremilast 30 mg BID0/187 (0%)17/187 (9.1%)132/187 (70.6%)
Open-label Extension Phase: Apremilast 30 mg BID0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg BIDApremilast Exposure Period: Apremilast 30 mg BIDOpen-label Extension Phase: Apremilast 30 mg BID
AppendicitisInfections and infestations0/1030/1042/1870/2
Behcet's syndromeVascular disorders0/1031/1042/1870/2
Mouth ulcerationGastrointestinal disorders1/1030/1040/1870/2
Diarrhoea infectiousInfections and infestations1/1030/1040/1870/2
Genital infectionInfections and infestations1/1030/1040/1870/2
Genital infection fungalInfections and infestations1/1030/1040/1870/2
Acute febrile neutrophilic dermatosisSkin and subcutaneous tissue disorders1/1030/1040/1870/2
Erythema multiformeSkin and subcutaneous tissue disorders1/1030/1040/1870/2
Skin lesionSkin and subcutaneous tissue disorders1/1030/1040/1870/2
Soft tissue injuryInjury, poisoning and procedural complications0/1031/1041/1870/2
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg BIDApremilast Exposure Period: Apremilast 30 mg BIDOpen-label Extension Phase: Apremilast 30 mg BID
DepressionPsychiatric disorders1/1030/1041/1872/2
Dry eyeEye disorders1/1030/1040/1871/2
ConstipationGastrointestinal disorders3/1030/1043/1871/2
DiarrhoeaGastrointestinal disorders21/10343/10474/1871/2
Impaired gastric emptyingGastrointestinal disorders0/1030/1040/1871/2
NauseaGastrointestinal disorders11/10320/10436/1871/2
Eye infectionInfections and infestations0/1030/1040/1871/2
Helicobacter infectionInfections and infestations0/1030/1040/1871/2
Urinary tract infectionInfections and infestations4/1031/1042/1871/2
Bone contusionInjury, poisoning and procedural complications0/1030/1040/1871/2

Baseline characteristics

The intent to treat (ITT) population was defined as all randomized participants who received at least 1 dose of investigational product (IP). Participants were included in the treatment group to which they were originally randomized.

Age, Continuous
Age, Continuous(Years)PlaceboApremilast 30 mg BIDTotal
Mean40.6 ± 12.6639.4 ± 12.1240.0 ± 12.37
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 30 mg BIDTotal
Female6364127
Male404080
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboApremilast 30 mg BIDTotal
American Indian or Alaska Native101
Asian303262
Native Hawaiian or Other Pacific Islander101
Black or African American011
White6869137
More than one race000
Unknown or Not Reported325
Region of the World
Region of the World(Participants)PlaceboApremilast 30 mg BIDTotal
Europe272552
North America111425
Asia293261
Rest of World363369
Duration of Behcet's Disease
Duration of Behcet's Disease(Years)PlaceboApremilast 30 mg BIDTotal
Mean6.94 ± 7.9666.74 ± 7.3976.84 ± 7.667
Oral Ulcer Count
Oral Ulcer Count(Oral ulcers)PlaceboApremilast 30 mg BIDTotal
Mean3.9 ± 2.704.2 ± 3.654.1 ± 3.21
Pain of Oral Ulcers Visual Analog Scale (VAS)
Pain of Oral Ulcers Visual Analog Scale (VAS)(mm)PlaceboApremilast 30 mg BIDTotal
Mean60.8 ± 26.9261.2 ± 27.5561.0 ± 27.17
Behçet's Disease Current Activity Index (BDCAI) Score
Behçet's Disease Current Activity Index (BDCAI) Score(Units on a scale)PlaceboApremilast 30 mg BIDTotal
Mean3.6 ± 1.673.7 ± 1.583.7 ± 1.62

2 further baseline measures are reported on the registry.

08

Study locations

63 sites
  • Arizona Arthritis and Rheumatology Research, PLLC
    Phoenix, Arizona 85032, United States
  • University of California Davis Medical Center
    Sacramento, California 95816, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Arthritis and Rheumatology of Georgia
    Atlanta, Georgia 30342, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Advanced Rheumatology
    Lansing, Michigan 48910, United States
  • Shores Rheumatology
    Saint Clair Shores, Michigan 48081, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • University of Pennsylvania Health Systems
    Philadelphia, Pennsylvania 19104, United States
  • Hopital de La Conception
    Marseille Cedex 05, 13385, France
  • Pitié-Salpêtriere Hospital Paris
    Paris, 75013, France
  • Hopital Cochin
    Paris, 75014, France
  • Hospital Saint Louis
    Paris, 75475, France
  • Charite Universitaetsmedizin Berlin
    Berlin, 10107, Germany
  • Stadtisches Klinikum Dessau
    Dessau, 06847, Germany
  • Asklepios Rheumazentrum Hamburg
    Hamburg, 22763, Germany
  • Navy Hospital of Athens
    Athens, 115 21, Greece
  • Athens General Hospital 'G Gennimatas'
    Athens, 115 27, Greece
  • Laiko General Hospital of Athens
    Athens, 11527, Greece
  • Ippokratio General Hospital of Thessaloniki
    Thessaloniki, 54642, Greece
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Rambam Health Care Campus
    Haifa, 31096, Israel
  • Hadassah Medical Organization
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petah Tikva, 49100, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Azienda Ospedaliero Universitaria Careggi
    Firenze, 50134, Italy
  • Azienda Ospedaliera Regionale San Carlo
    Potenza/Matera, 85100, Italy
  • Arcispedale Santa Maria Nuova
    Reggio Emilia, 42100, Italy
  • Medical Hospital of Tokyo Medical and Dental University
    Bunkyo-ku, Tokyo, 113-8519, Japan
  • Nippon Medical School Hospital
    Bunkyo-ku, 113-8602, Japan
  • St. Luke's International Hospital
    Chuo-ku, 104-8560, Japan
  • Tokyo Metropolitan Tama Medical Center
    Fuchu-shi, 183-8524, Japan
  • Japanese Red Cross Society Himeji Hospital
    Himeji-shi, 670-8540, Japan
  • Saitama Medical University Hospital
    Iruma-gun, Saitama, 350-0495, Japan
  • Teikyo University Hospital
    Itabashi-ku, 173-8606, Japan
  • Nihon University Itabashi Hospital
    Itabashi-ku, 173-8610, Japan
  • St Marianna University School of Medicine Hospital
    Kawasaki, Kanagawa, 216-8511, Japan
  • University of Occupational and Environmentall Health
    Kitakyushu, 807-8556, Japan
  • Kagawa University Hospital
    Miki-cho, 761-0793, Japan
  • Kitasato University Hospital
    Sagamihara, 228-8555, Japan
  • Saga Medical School Hospital
    Saga, 849-8501, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaidô, 060-8543, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaidô, 060-8648, Japan
  • Shimonoseki City Hospital
    Shimonoseki, 750-8520, Japan
  • Tokyo Medical University Hospital
    Shinjyuku-ku, 160-0023, Japan
  • Tomishiro Central Hospital
    Tomigusuku-shi, 901-0243, Japan
  • Ehime University Hospital
    Toon, 791-0295, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa, 213-8507, Japan
  • Chungnam National University Hospital
    Daejeon, 302799, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 120-752, Korea, Republic of
  • Konkuk University Hospital
    Seoul, 143-729, Korea, Republic of
  • Ajou University Hospital
    Suwon si, 16499, Korea, Republic of
  • Hotel Dieu de France
    Beirut, Lebanon
  • Ain Wazein Hospital
    El Chouf, Lebanon
  • American University of Beirut Medical Center
    El Chouf, Lebanon
  • Cukurova University Medical Faculty Balcali Hospital
    Adana, 01330, Turkey
  • Eskisehir Osmangazi University
    Eskisehir, 26480, Turkey
  • Istanbul Universitesi Cerrahpasa Tip Fakultesi
    Istanbul, 34098, Turkey
  • Marmara University Hospital
    Istanbul, 34899, Turkey
  • Selcuk University Medical Faculty
    Konya, 42080, Turkey
09

References and documents

Publications

  • Hatemi G, Mahr A, Takeno M, Kim D, Melikoglu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Impact of apremilast on quality of life in Behcet's syndrome: analysis of the phase 3 RELIEF study. RMD Open. 2022 Jul;8(2):e002235. doi: 10.1136/rmdopen-2022-002235. PubMed 35798511 ↗
  • Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, Melikoglu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Trial of Apremilast for Oral Ulcers in Behcet's Syndrome. N Engl J Med. 2019 Nov 14;381(20):1918-1928. doi: 10.1056/NEJMoa1816594. PubMed 31722152 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2014 to primary completion in Sep 2017, 32 months.

Results were first posted in Sep 2019, 1 year 11 months after primary completion. A results delay was requested in Jan 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2014
First posted
Dec 4, 2014
StartActual
Dec 30, 2014
Primary completionActual
Sep 25, 2017
CompletionActual
Jul 17, 2020
Results delay requested
Jan 10, 2018
Results first posted
Sep 11, 2019
Last update
Jul 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02307513
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Dec 30, 2014
Primary completion
Sep 25, 2017
Completion
Jul 17, 2020
Results posted
Sep 11, 2019
Last update
Jul 22, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion